Images
ABC has published an article on a study led by Modesto Orozco, head of the Molecular Modelling and Bioinformatics Lab at IRB Barcelona. This work has unravelled the mechanism of action of the mAb806 antibody, a drug used to treat glioblastoma. Published in the journal PNAS, the study lays the foundation for the extension of this treatment to more types of tumours and to more specific therapies.
Link to ABC
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
